| Patient | Jacqueline Mary du Pré |
|---|---|
| Date of birth | 1998-01-26 |
| Identifiers | MRN HR-ML039-SYN; SSN (made up) 000-39-7062 |
| Document date | 2026-04-27 |
| Author | Imogen Thackeray-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Second half-dose of the first ocrelizumab course. [S]
Ms. du Pré comes on the day of her second 300 mg dose of ocrelizumab. The three days of intravenous methylprednisolone a month ago caused a few nights of poor sleep and a metallic taste, and within two weeks the feeling in her fingers began to come back. The first infusion two weeks ago caused an itchy throat and flushing an hour in, which settled when the rate was slowed. She has worked with the occupational therapist on finger exercises and practices in 20-minute blocks, about two hours a day, and has played through slow movements without losing her place. The electric feeling on bending her head is fainter. Her blood tests before the first infusion were normal. She is less tired. [S]
| Element | Detail |
|---|---|
| Treatment | Methylprednisolone 1 g for 3 days; ocrelizumab 300 mg two weeks ago; second 300 mg today |
| Infusion reaction | Mild throat itch and flushing with the first dose, settled by slowing the rate |
| Hand function | Feeling returning; practicing two hours a day in short blocks |
| Vaccination | Hepatitis B dose 2 today |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Less tired; no fever |
| Neurological | Positive | Tingling in the left fingertips, less than before; Lhermitte's sign fainter; no new symptoms |
| Ears, nose, mouth, and throat | Negative | Throat itch with the first infusion only |
| Genitourinary | Negative | No urinary symptoms |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Hopeful; PHQ-9 5; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days | 1 g daily for 3 days | Intravenous route | 2026-03-24 to 2026-03-26 | completed | S |
| Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily | One capsule daily | Oral route | 2026-03-23 | active | S |
| Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion | 300 mg on days 1 and 15, then 600 mg every 6 months | Intravenous route | 2026-04-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-27 | Body height | 173 | cm | S |
| 2026-04-27 | Body weight | 64.6 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 72 | /min | S |
| 2026-04-27 | Respiratory rate | 14 | /min | S |
| 2026-04-27 | Body temperature | 36.6 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-27 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-04-27 | Leukocytes [#/volume] in Blood by Automated count | 7.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-27 | Lymphocytes [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-04-27 | Platelets [#/volume] in Blood by Automated count | 252 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-27 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 2026-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-35 U/L | Normal | S |
| 2026-04-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-04-27 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 20.5 | s | S | ||
| 2026-04-27 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 23 | s | S |
Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 64.6 kg, up 1.2 kg after steroids; blood pressure 118/74 |
| Neurological | Vibration and joint position sense now only slightly reduced in the left fingers; no wandering of the fingers; strength normal; Lhermitte's sign faint. Nine-hole peg test 20.5 seconds right, 23.0 seconds left |
| Skin | No rash |
| Psychiatric | Brighter and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | R20.2 | S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit. |
| Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 2017 McDonald criteria and the 2024 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | G35.A | S — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973. |
| Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | E55.9 | S — Synthetic finding. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with lymphocytes | Before each ocrelizumab dose | Completed today | Hemoglobin 13.6 g/dL, white cells 7.9, lymphocytes 1.6, platelets 252 |
| Laboratory | Liver tests and glucose | After high-dose steroids and before each dose | Completed today | ALT 21 U/L, AST 22 U/L; glucose 90 mg/dL |
| Laboratory | Pregnancy test | Before each ocrelizumab dose | Completed today | Urine pregnancy test negative |
| Laboratory | Hepatitis B, HIV and other screening before B-cell therapy | Before the first dose | Up to date | Reviewed at the diagnosis visit: no hepatitis B infection and not immune, so vaccination continues |
| Medication safety | Infusion reactions | With each infusion | Completed today | Mild reaction with dose 1 (throat itch, flushing); premedication and a slower rate today |
| Medication safety | Vaccination | Complete series where possible | Completed today | Hepatitis B dose 2 today; recombinant zoster dose 2 due in two to six months after dose 1 |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 20.5 seconds right, 23.0 seconds left |
| Referral | Occupational therapy | Through recovery from the relapse | Up to date | Program started a week after the diagnosis visit |
| Imaging | Re-baseline MRI of the brain | Three to six months after starting a disease-modifying therapy | Due | Booked for about three months after the first dose |
| Laboratory | 25-hydroxyvitamin D | About three months after starting replacement | Due | With the re-baseline MRI visit |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 5; item 9 scored 0 |
| Self-management | Fatigue: causes and management | Each review | Completed today | Less tired; pacing practice in short blocks with rests |
Goal progress:
Immunizations given today: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 [S]
Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376(3):221-234 (PMID 28002679) (2017); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)
Follow-up: Re-baseline MRI and review in about ten weeks; occupational therapy continues; call for fever, urinary symptoms or any new neurological symptom. Next scheduled visit 2026-07-13: three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function. [S]